AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for Rare Immunodeficiency Disorder, ADA-SCID

AGC Biologics announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity’s gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the US Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the US.